Immutep Limited American Depositary Shares — Chart, Price & News (NASDAQ:IMMP)

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Market Capitalization N/A
Employee 51
Founded 2001
CEO Marc Voigt
Website www.immutep.com
Headquarter Australia
FIGI BBG002WD6SY6
Industry Technology

Total revenue

Net income

Basic earnings per share (Basic EPS)

Total debt

Free cash flow

Cash & equivalents

— Market capitalization

Price to earnings ratio

—

Price to sales ratio

—

Dividends per share

—

Dividend yield %

—

Immutep Limited - American Depositary Shares

Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech. Prima currently has three main products in its pipeline, all acquired with Immutep: Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer. IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline. IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis.